Business Wire

Torq Lands Virgin Atlantic CISO John White to Lead Enterprise Shift to Agentic AI

4.2.2026 15:00:00 CET | Business Wire | Press Release

Share

Torq, the established agentic security operations leader, today announced former Virgin Atlantic CISO John White has joined Torq as Field CISO. Following Torq’s $140M Series D, White shifts from the customer side to the Torq leadership team, propelling global enterprise CISOs to modernize their strategies and adopt true Agentic AI.

White is a highly respected security executive with more than 20 years of leadership experience. Prior to Virgin Atlantic, he built and transformed security functions for global organizations including ASOS, Liberty Global, AEG Europe, and KPMG, spanning retail, telecommunications, energy, and live entertainment.

At Virgin Atlantic, White did not just oversee security, he reinvented it. Leading a multi-year transformation across airline, cargo, and vacation businesses, White deployed the Torq AI SOC Platform to modernize its cyber operations. The result was a dramatic increase in protection and efficiency that convinced him the industry had reached a pivotal moment.

“I’m thrilled to join Torq as agentic SOC innovation meets market momentum at hyperscale,” said White. “Having seen firsthand how the Torq AI SOC Platform accelerates triage, investigation, and response across complex IT environments, I’m excited to help lead Torq customers and prospects into this incredible new era. The Torq AI SOC Platform proves AI is no longer optional. Instead of creating conventional org charts, I encourage CISOs everywhere to put up an agentic workforce chart and ensure their SOC team is aligned with its capabilities and potential. It’s official: Agentic AI is now the core architecture of the modern SOC.”

As a strategic partner for security leaders In his new role, White serves as a consultative peer to Torq’s community of CISOs and security stakeholders. He focuses on CISO-to-CISO engagement, helping security teams cut through the noise of the market, and implement practical, outcome-driven Agentic AI strategies. His mandate is to bridge the gap between technical potential and executive strategy for Torq’s customer base, which includes Marriott, PepsiCo, Procter & Gamble, Siemens, and Uber.

“Bringing John White on board reflects our commitment to a practitioner-led approach,” said Ofer Smadari, CEO and co-founder, Torq. “John isn’t a theorist. Rather, he has the battle scars from running mission-critical security at a global airline. He understands the pressure CISOs face because he was in their seat just yesterday. He chose to join Torq to help the industry move faster, and his experience will be invaluable to every security leader looking to fix their SOC.”

About Torq

Torq is transforming cybersecurity with the Torq AI SOC platform. Torq empowers enterprises to instantly and precisely detect and respond to security events at scale. Torq’s customer base includes major multinational enterprise customers, including Abnormal Security, Armis, Check Point Security, Chipotle Mexican Grill, Inditex (Zara, Bershka, and Pull & Bear), Informatica, Kyocera, PepsiCo, Procter & Gamble, Siemens, Telefónica, Valvoline, Virgin Atlantic, and Wiz.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260204167249/en/

Contacts

Media Contact
torq@teamhighwire.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye